Cite
Michal M, Eggebrecht L, Göbel S, et al. The relevance of depressive symptoms for the outcome of patients receiving vitamin K antagonists: results from the thrombEVAL cohort study. Eur Heart J Cardiovasc Pharmacother. 2021;7(4):271-279doi: 10.1093/ehjcvp/pvz085.
Michal, M., Eggebrecht, L., Göbel, S., Panova-Noeva, M., Nagler, M., Arnold, N., Lauterbach, M., Bickel, C., Wiltink, J., Beutel, M. E., Münzel, T., Wild, P. S., & Prochaska, J. H. (2021). The relevance of depressive symptoms for the outcome of patients receiving vitamin K antagonists: results from the thrombEVAL cohort study. European heart journal. Cardiovascular pharmacotherapy, 7(4), 271-279. https://doi.org/10.1093/ehjcvp/pvz085
Michal, Matthias, et al. "The relevance of depressive symptoms for the outcome of patients receiving vitamin K antagonists: results from the thrombEVAL cohort study." European heart journal. Cardiovascular pharmacotherapy vol. 7,4 (2021): 271-279. doi: https://doi.org/10.1093/ehjcvp/pvz085
Michal M, Eggebrecht L, Göbel S, Panova-Noeva M, Nagler M, Arnold N, Lauterbach M, Bickel C, Wiltink J, Beutel ME, Münzel T, Wild PS, Prochaska JH. The relevance of depressive symptoms for the outcome of patients receiving vitamin K antagonists: results from the thrombEVAL cohort study. Eur Heart J Cardiovasc Pharmacother. 2021 Jul 23;7(4):271-279. doi: 10.1093/ehjcvp/pvz085. PMID: 31922545.
Copy
Download .nbib